Aerolase and Eucerin entered into a mutual agreement in the D-A-CH-region (Germany-Austria-Switzerland) aimed at optimizing laser treatment protocols for enhanced patient benefits. In addition, both companies will develop therapies for adjunctive care post-laser treatments. Eucerin products were available at the Aerolase booth during the IMCAS World Congress, which took place from January 30 to February 2 in Paris. "We see great potential in this collaboration, and are confident the laser and adjunctive care protocols will elevate standards of care," says Pavel Efremkin Ph.D, chairman and CEO of Aerolase. "Future breakthrough therapies will likely come through innovative clinical research, technologies, and proprietary combination treatments."